Document 0075
 DOCN  M9440075
 TI    Adoptive immunotherapy with purified NK or T cells (Meeting abstract).
 DT    9404
 AU    Herberman RB; Pittsburgh Cancer Inst., Pittsburgh, PA
 SO    Biological Response Modifiers, 2nd International Congress. January
       29-31. 1993, San Diego, CA, p. 79, 1993.. Unique Identifier : AIDSLINE
       ICDB/94698353
 AB    Adoptive transfer of peripheral blood lymphocytes with
       lymphokine-activated killer (LAK) activity or of tumor infiltrating
       lymphocytes, together with high doses of interleukin 2 (IL2), has been
       shown to have therapeutic efficacy against metastatic tumors in some
       experimental animal models and in some cancer patients, particularly
       those with renal cell carcinoma or melanoma. However, the frequency of
       objective responses has been low and the high doses of IL2 utilized have
       contributed to substantial toxicity. The challenge is to develop second
       generation therapeutic protocols, to optimize therapeutic efficacy and
       to reduce toxicity. We have focused on the use of defined, highly
       purified lymphocyte populations which have been shown to contain
       cytolytic effector cells. Since LAK activity in peripheral blood is
       generated predominantly from natural killer (NK) cells, we have
       developed a procedure to consistently isolate highly enriched
       populations of IL2 activated NK cells, based on the ability of a subset
       of such cells to adhere to plastic. These A-NK cells, when administered
       together with moderate doses of IL2, have been shown to have potent
       antimetastatic effects against several experimental tumors in mice or
       rats. Transfer of fluorescently labeled A-NK cells has shown selective
       accumulation of a small proportion of the effector cells in sites of
       metastasis. A preliminary clinical trial with autologous A-NK cells has
       demonstrated the feasibility of this approach in advanced cancer
       patients. An analogous approach has recently been utilized for the
       treatment of HIV-infected individuals, in which autologous CD8+ T cells
       have been isolated by a solid phase capture device (Applied Immune
       Sciences), expanded in culture with IL2, and infused iv. These purified
       T cells have been shown to have significant and specific cytotoxic
       activity against HIV-infected target cells and a separate clinical trial
       at the University of Miami (N Klimas, PI) has shown objective responses
       in some patients with Kaposi's sarcoma.
 DE    Animal  HIV Infections/IMMUNOLOGY  *Immunotherapy  Kidney
       Neoplasms/IMMUNOLOGY/*THERAPY  *Killer Cells, Lymphokine-Activated
       *Killer Cells, Natural  Melanoma/IMMUNOLOGY/*THERAPY  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).